3 news items
Larimar Therapeutics Selected by FDA to Participate in START Pilot Program for Nomlabofusp in Friedreich's Ataxia
LRMR
30 May 24
with this devastating disease." Nomlabofusp is currently being evaluated in an ongoing open label extension (OLE) study to assess the long-term
Larimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich's Ataxia
LRMR
20 May 24
, and assessments; that the FDA may not ultimately agree with Larimar's nomabofusp development strategy; the potential impact of public health crises
Larimar Therapeutics Reports First Quarter 2024 Operating and Financial Results
LRMR
9 May 24
of 2024. In addition, clinical assessments collected during the study will be compared to data from a matched control arm derived from participants
- Prev
- 1
- Next